Bronnen:
Mok T, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase 3 trial. J Clin Oncol 35, 2017 (suppl; abstr LBA9007).
Mok T, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase 3 trial. J Clin Oncol 35, 2017 (suppl; abstr LBA9007).